Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response?

Drug Resistance Updates

Volumn 1, Issue 1, 1998, Pages 11-15

  Odds, Frank C ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002621945     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80209-4     Document Type: Review

References (25)

1. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A (1997), NCCLS
2. Moore R.D., Lietman P.S., and Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155 (1987) 93-99
3. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In: Lorian V. (Ed). Antibiotics in Laboratory Medicine. 4th edn (1996), William & Wilkins, Baltimore 52-111
4. Greenwood D. In vitro veritas. Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis 144 (1981) 380-385
5. Barchiesi F., Hollis R.J., Mcgough D.A., Scalise G., Rinaldi M.G., and Pfaller M.A. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis 20 (1995) 634-640
6. Espinel-Ingroff A., Rodriguez-Tudela J.L., and Martinez-Suarez J.V. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J Clin Microbiol 33 (1995) 3154-3158
7. Rex J.H., Pfaller M.A., Barry A.L., Nelson P.W., and Webb C.D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 39 (1995) 40-44
8. Phillips P., Zemcov J., Mahmood W., Montaner J.S.G., Craib K., and Clarke A.M. Itraconazole cyclodextrin solution for fluconazole refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 10 (1996) 1369-1376
9. Quereda C., Polanco A.M., Giner C., et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 15 (1996) 30-37
10. Rex J.H., Pfaller M.A., Galgiani J.N., et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 24 (1997) 235-247
11. Johnson C.C. In vitro testing: correlations of bacterial susceptibility, body fluid levels, and effectiveness of antibacterial therapy. In: Lorian V. (Ed). Antibiotics in Laboratory Medicine. 4th edn (1996), William & Wilkins, Baltimore 813-834
12. Lorian V., Burns L., and Ernst J. Predictive value of susceptibility tests for the outcome of antibacterial therapy. J Antimicrob Chemother 25 (1990) 175-181
13. Flick M.R., and Cluff L.E. Pseudomonas bacteremia: review of 108 cases. Am J Med 60 (1976) 501-508
14. Gerber A.U., and Craig W.A. Worldwide clinical experience with cefoperazone. Drugs 22 Suppl 1 (1981) 108-118
15. (Suppl). Thornsberry C., Jones R.N., Barry A.L., and Fuchs P.C. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response. Rev Infect Dis 4 (1982) S316-S324
16. Kreger B.E., Craven D.E., and McCabe W.R. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68 (1980) 344-354
17. Bryan C.S., Reynolds K.L., and Brenner E.R. Analysis of 1186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 5 (1983) 629-638
18. Dupont M.J., and Lapointe J.R. Effects of Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to Pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. J Antimicrob Chemother 36 (1995) 231-236
19. Hostacka A. Postantibiotic effects of subinhibitory concentrations of some antibiotics and their influence on Pseudomonas aeruginosa enzymic activity. Folia Microbiol 41 (1996) 39-42
20. Angiolella L., Facchin M., Stringaro A., Maras B., Simonetti N., and Cassone A. Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. J Infect Dis 173 (1996) 684-690
21. Miglioli P.A., Schoffel U., and Gianfranceschi L. The in vitro synergistic inhibitory effect of human amniotic fluid and gentamicin on growth of Escherichia coli. Chemotherapy 42 (1996) 206-209
22. Maenza J.R., Merz W.G., Romagnoli M.J., Keruly J.C., Moore R.C., and Gallant J.E. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 24 (1997) 28-34
23. Dronda F., Alonsosanz M., Laguna F., et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. J Clin Microbiol Infect Dis 15 (1996) 446-452
24. Pittrow L., and Penk A. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints. Mycoses 40 (1997) 25-32
25. Ghannoum M.A., Rex J.H., and Galgiani J.N. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 34 (1996) 489-495